Skip to main content
Clinical Trials/NCT06277206
NCT06277206
Completed
Not Applicable

A Study Using 18F-FAPI PET to Evaluate Pathologic Response to Systemic Treatment in Pancreatic Adenocarcinoma

Zhejiang University1 site in 1 country59 target enrollmentAugust 4, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
18F-FAPI
Sponsor
Zhejiang University
Enrollment
59
Locations
1
Primary Endpoint
Change of Mean standardized uptake value
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

To explore the potential utility of 18F-FAPI-04 PET/CT for pathologic response evaluation to systemic treatment in PDAC

Registry
clinicaltrials.gov
Start Date
August 4, 2021
End Date
February 10, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Zhejiang University
Responsible Party
Principal Investigator
Principal Investigator

TingBo Liang

Professor

Zhejiang University

Eligibility Criteria

Inclusion Criteria

  • suspected to have pancreatic cancer by radiological imaging
  • planned systemic treatment
  • possibility of conversion surgery
  • willingness to participate the study

Exclusion Criteria

  • without pathologically confirmed pancreatic cancer
  • poor performance status or organ functions that cannot meet the systemic treatment requirements
  • metastatic disease
  • pregnant patients

Outcomes

Primary Outcomes

Change of Mean standardized uptake value

Time Frame: Baseline and preoperation

Change of SUVmean before and after treatment

Change of Maximum standardized uptake value

Time Frame: Baseline and preoperation

Change of SUVmax before and after treatment

Secondary Outcomes

  • Mean standardized uptake value(Baseline)
  • Change of Total Lesion FAP expression(Baseline and preoperation)
  • Maximum standardized uptake value(Baseline)
  • Metabolic Tumor Volume(Baseline)
  • Change of Metabolic Tumor Volume(Baseline and preoperation)
  • Total Lesion FAP expression(Baseline)

Study Sites (1)

Loading locations...

Similar Trials